Beth Faiman, Hoa H Le, Julie Laurent, Saurabh Patel, Agne Paner-Straseviciute, Xinke Zhang, Joseph Mikhael
{"title":"离散选择实验分析，了解患者对多发性骨髓瘤治疗的偏好。","authors":"Beth Faiman, Hoa H Le, Julie Laurent, Saurabh Patel, Agne Paner-Straseviciute, Xinke Zhang, Joseph Mikhael","doi":"10.3389/fonc.2025.1628121","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options.</p><p><strong>Methods: </strong>This study was designed as a non-interventional descriptive cross-sectional study based on an online discrete choice experiment (DCE) among adult RRMM patients living in the between USA November 2023 and March 2024. The survey included attributes and levels derived from an extensive literature review and guided interviews conducted with MM patients. Preference data were analyzed using a conditional logistic (CL) regression model and relative attribute importance (RAI) scores were calculated. Patients' willingness to trade off overall response rate (ORR) was evaluated using the partworth utilities estimated from the CL model.</p><p><strong>Results: </strong>149 MM patients completed the survey; 66% had received 1-2 prior lines of therapy, 15% three prior lines, 19% four or more prior lines. Patients significantly preferred treatments with longer progression-free survival (PFS) and overall survival (OS) and higher ORR (RAI: 36.4% and 22.1%, respectively). With respect to adverse events assessed in this study, patients expressed concern for cytokine release syndrome (CRS) (RAI: 15.2%) and infections (RAI: 11.9%). In contrast, nail/skin disorders, duration of hospitalization, and taste disorder were less important to patients. Patients would be willing to accept a high risk of CRS (72% over no risk) to gain 29% increase in ORR.</p><p><strong>Conclusions: </strong>Patients showed a clear preference for treatment efficacy (PFS/OS and ORR). This study confirmed patients' valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1628121"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479298/pdf/","citationCount":"0","resultStr":"{\"title\":\"A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments.\",\"authors\":\"Beth Faiman, Hoa H Le, Julie Laurent, Saurabh Patel, Agne Paner-Straseviciute, Xinke Zhang, Joseph Mikhael\",\"doi\":\"10.3389/fonc.2025.1628121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options.</p><p><strong>Methods: </strong>This study was designed as a non-interventional descriptive cross-sectional study based on an online discrete choice experiment (DCE) among adult RRMM patients living in the between USA November 2023 and March 2024. The survey included attributes and levels derived from an extensive literature review and guided interviews conducted with MM patients. Preference data were analyzed using a conditional logistic (CL) regression model and relative attribute importance (RAI) scores were calculated. Patients' willingness to trade off overall response rate (ORR) was evaluated using the partworth utilities estimated from the CL model.</p><p><strong>Results: </strong>149 MM patients completed the survey; 66% had received 1-2 prior lines of therapy, 15% three prior lines, 19% four or more prior lines. Patients significantly preferred treatments with longer progression-free survival (PFS) and overall survival (OS) and higher ORR (RAI: 36.4% and 22.1%, respectively). With respect to adverse events assessed in this study, patients expressed concern for cytokine release syndrome (CRS) (RAI: 15.2%) and infections (RAI: 11.9%). In contrast, nail/skin disorders, duration of hospitalization, and taste disorder were less important to patients. Patients would be willing to accept a high risk of CRS (72% over no risk) to gain 29% increase in ORR.</p><p><strong>Conclusions: </strong>Patients showed a clear preference for treatment efficacy (PFS/OS and ORR). This study confirmed patients' valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1628121\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479298/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1628121\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1628121","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments.
Introduction: Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options.
Methods: This study was designed as a non-interventional descriptive cross-sectional study based on an online discrete choice experiment (DCE) among adult RRMM patients living in the between USA November 2023 and March 2024. The survey included attributes and levels derived from an extensive literature review and guided interviews conducted with MM patients. Preference data were analyzed using a conditional logistic (CL) regression model and relative attribute importance (RAI) scores were calculated. Patients' willingness to trade off overall response rate (ORR) was evaluated using the partworth utilities estimated from the CL model.
Results: 149 MM patients completed the survey; 66% had received 1-2 prior lines of therapy, 15% three prior lines, 19% four or more prior lines. Patients significantly preferred treatments with longer progression-free survival (PFS) and overall survival (OS) and higher ORR (RAI: 36.4% and 22.1%, respectively). With respect to adverse events assessed in this study, patients expressed concern for cytokine release syndrome (CRS) (RAI: 15.2%) and infections (RAI: 11.9%). In contrast, nail/skin disorders, duration of hospitalization, and taste disorder were less important to patients. Patients would be willing to accept a high risk of CRS (72% over no risk) to gain 29% increase in ORR.
Conclusions: Patients showed a clear preference for treatment efficacy (PFS/OS and ORR). This study confirmed patients' valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.
期刊介绍：
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
